CN113930348A - Yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as substrate, construction and application thereof - Google Patents

Yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as substrate, construction and application thereof Download PDF

Info

Publication number
CN113930348A
CN113930348A CN202111107802.9A CN202111107802A CN113930348A CN 113930348 A CN113930348 A CN 113930348A CN 202111107802 A CN202111107802 A CN 202111107802A CN 113930348 A CN113930348 A CN 113930348A
Authority
CN
China
Prior art keywords
yarrowia lipolytica
plasmid
glycyrrhetinic acid
strain
module
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202111107802.9A
Other languages
Chinese (zh)
Other versions
CN113930348B (en
Inventor
赵云现
李迪
杨志彬
崔金旺
田昊博
胡江林
展全乐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hebei Weidakang Biotechnology Co ltd
Original Assignee
Hebei Weidakang Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hebei Weidakang Biotechnology Co ltd filed Critical Hebei Weidakang Biotechnology Co ltd
Priority to CN202111107802.9A priority Critical patent/CN113930348B/en
Publication of CN113930348A publication Critical patent/CN113930348A/en
Application granted granted Critical
Publication of CN113930348B publication Critical patent/CN113930348B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/905—Stable introduction of foreign DNA into chromosome using homologous recombination in yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C12N9/0038—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12N9/0042—NADPH-cytochrome P450 reductase (1.6.2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P33/00—Preparation of steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/02—Oxidoreductases acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12Y106/02004—NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13134—Beta-amyrin 11-oxidase (1.14.13.134)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y504/00—Intramolecular transferases (5.4)
    • C12Y504/99—Intramolecular transferases (5.4) transferring other groups (5.4.99)
    • C12Y504/99039—Beta-amyrin synthase (5.4.99.39)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention discloses a yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as a substrate, and construction and application thereof, and belongs to the technical field of biology. The engineering strain integrates a beta-balsamic alcohol synthase expression module, an 11/30 th-oxidation-beta-balsamic enzyme expression module, a cell P450 oxidase expression module and a cytochrome P450 reductase expression module on a genome; the construction steps are as follows: constructing and obtaining glycyrrhetinic acid biosynthesis module plasmid: beta-balsamic alcohol synthetase bAS, cytochrome P450 oxidase 88D6CYP88D6, 11/30-oxidation-beta-balsamic alcohol CYP725A4, cytochrome P450 reductase CPR, integrating the glycyrrhetinic acid biosynthesis module on yarrowia lipolytica tool plasmid, linearizing the plasmid integrated with the glycyrrhetinic acid biosynthesis module, and introducing the linearized plasmid into yarrowia lipolytica to obtain yarrowia lipolytica engineering bacteria with the glycyrrhetinic acid biosynthesis module integrated on the genome. The yield of glycyrrhetinic acid produced by the engineering strain is obviously improved and reaches up to 7 g/L.

Description

Yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as substrate, construction and application thereof
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as a substrate, construction and application thereof.
Background
The liquorice is a traditional Chinese medicine for tonifying qi, and is the most widely used traditional Chinese medicine in clinic. The glycyrrhiza is sweet in taste and neutral in nature, enters heart, spleen, lung and stomach meridians, has the effects of tonifying spleen and qi, moistening lung and arresting cough, clearing heat and removing toxicity, relieving pain, moderating drug properties and the like, and has the advantages that glycyrrhetinic acid and glycyrrhizic acid are main medicinal components in the glycyrrhiza, wherein the glycyrrhetinic acid is a precursor for glycyrrhizic acid biosynthesis and has similar pharmacological and physiological activities to the glycyrrhizic acid. Research shows that glycyrrhetinic acid has the functions of regulating immunity, resisting allergy and resisting virus infection, and has inhibiting effect on oncogenic virus infection, such as hepatitis virus, EB virus and AIDS virus. Due to the wide medicinal value and economic value, the production of the glycyrrhetinic acid is well pursued by enterprises. At present, the synthesis method of glycyrrhetinic acid mainly comprises a solvent extraction method, wherein glycyrrhetinic acid powder is obtained by carrying out a plurality of steps of extraction, separation, precipitation, drying and the like on liquorice, and glycyrrhetinic acid is obtained by extraction and crystallization. The method for producing glycyrrhetinic acid by using saccharomyces cerevisiae as a host bacterium and using a synthetic biology method is also available, but the method is only in a stage of synthesizing glycyrrhetinic acid by using glycyrrhizic acid as a precursor.
The invention provides an operation method for biologically synthesizing glycyrrhetinic acid, in particular to a method for producing glycyrrhetinic acid from the beginning by using yarrowia lipolytica and glucose as a substrate.
Disclosure of Invention
In order to solve the technical problems, the invention aims to provide a construction method and application of a yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as a substrate.
A method for constructing yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as a substrate comprises the following steps: constructing and obtaining glycyrrhetinic acid biosynthesis expression module plasmid: beta-amyrin synthase bAS expression module plasmid, cytochrome P450 oxidase 88D6CYP88D6 expression module plasmid, 11/30-oxidation-beta-amyrin synthase CYP725A4 expression module plasmid and cytochrome P450 reductase CPR expression module plasmid, integrating the glycyrrhetinic acid biosynthesis module on yarrowia lipolytica tool plasmid, linearizing the plasmid integrated with the glycyrrhetinic acid biosynthesis module, and introducing the linearized plasmid into yarrowia lipolytica to obtain yarrowia lipolytica engineering bacteria integrated with the glycyrrhetinic acid biosynthesis module on the genome.
In the above scheme, the lanosterol synthase (ERG7) site of yarrowia lipolytica genome is knocked out in a recombinant manner, and squalene oxidase (ERG1) and squalene synthase (ERG9) are expressed and integrated at the site, so that metabolic flow is guided to 2, 3-oxidosqualene.
According to the above scheme, the above scheme further comprises the following recombination modification of yarrowia lipolytica genome: the flux of the MVA metabolic pathway is enhanced by overexpression of truncated hydroxymethylglutarate reductase (trHMGR) and hydroxymethylglutarate synthetase (HMGS). The truncated range of the truncated hydroxymethylglutarate reductase (trHMGR) is the first 300-500 amino acid sequences from the N-terminal of the protein, the more preferable range of the truncated range is the first 450-500 amino acid sequences from the N-terminal of the protein, and the most preferable range of the truncated sequence is the first 500 amino acid sequences from the N-terminal of the protein.
In the above protocol, the method further comprises integrating cytochrome b5 into the yarrowia lipolytica strain.
According to the scheme, the cytochrome b5 gene sequence is shown in SEQ ID NO.9 and is derived from trypanosoma griseum.
According to the above scheme, the yarrowia lipolytica tool plasmid is a single-copy integration plasmid or a multi-copy integration plasmid.
According to the scheme, the single-copy integrated plasmid is pINA1269 plasmid; the multicopy integration plasmid is pINA 1292. Integrating the glycyrrhetinic acid biosynthesis module into a multicopy integration plasmid such as pINA1292 plasmid to construct a multicopy integration plasmid of the glycyrrhetinic acid biosynthesis module, linearizing the plasmid, and integrating into the genome of the yarrowia lipolytica to obtain the yarrowia lipolytica engineering bacteria integrating a plurality of glycyrrhetinic acid biosynthesis modules on the genome of the yarrowia lipolytica.
A preferable implementation and construction mode of the invention is as follows:
1) attenuating yarrowia lipolytica strain lanosterol synthase expression, overexpressing squalene oxidase (ERG1) and squalene synthase (ERG 9); 2) the strong promoter regulates and controls the expression of key enzymes (HMGS and HMGR truncation) of the self mevalonate pathway of the strain obtained in the step 1); 3) increasing the copy number of 2) the glycyrrhetinic acid heterologous pathway enzyme of the obtained strain on a genome; 4) overexpression in the strain obtained in 3) was derived from cytochrome b 5.
Provides a yarrowia lipolytica engineering strain for producing glycyrrhetinic acid, wherein bAS, CYP88D6, CYP725A4 and CPR genes are integrated in the yarrowia lipolytica engineering strain genome, and the yarrowia lipolytica engineering strain has the capability of synthesizing the glycyrrhetinic acid by using glucose as a substrate and through beta-balsamic alcohol, 11-beta-balsamic alcohol and 30-hydroxyl-11-balsamic alcohol oxide.
According to the scheme, the lanosterol synthase (ERG7) site is knocked out from the genome of the yarrowia lipolytica engineering strain, and squalene oxidase (ERG1) and squalene synthase (ERG9) are integrated and expressed at the site.
According to the scheme, the genome of the yarrowia lipolytica engineering strain overexpresses truncated hydroxymethylglutarate reductase (trHMGR) and hydroxymethylglutarate synthetase (HMGS). The truncated range of the truncated hydroxymethylglutarate reductase (trHMGR) is the first 300-500 amino acid sequences from the N-terminal of the protein, more preferably the truncated range is the first 450-500 amino acid sequences from the N-terminal of the protein, and the most preferred truncated sequence is the first 500 amino acid sequences from the N-terminal of the protein.
According to the scheme, cytochrome b5 is integrated on the genome of the yarrowia lipolytica engineering strain.
Provides an application of yarrowia lipolytica engineering strain for producing glycyrrhetinic acid in the synthesis of glycyrrhetinic acid by taking glucose as a substrate.
According to the scheme, the application method comprises the following steps:
culturing yarrowia lipolytica engineering strain for producing glycyrrhetinic acid to obtain seed solution;
inoculating the seed liquid into a fermentation culture medium containing glucose and metal elements and nutrient substances necessary for growth of yarrowia lipolytica, and performing fed-batch fermentation, wherein the pH control range in the fermentation process is 5.6-6.4; fed-batch glucose was controlled at a concentration of 20-40 g/L.
According to the scheme, the fermentation temperature is 28-32 ℃; the fermentation time is preferably 120h to 150 h.
Yarrowia lipolytica can enhance the generation of MVA by ingesting cheap substrate glucose through high flux acetyl coenzyme A of glycyrrhetinic acid to MVA and then to 2.3 oxidosqualene through over-expressing truncated trHMGR and HMGS, and simultaneously enhance the synthesis of 2.3 oxidosqualene through over-expressing ERG1 and ERG9, thereby further increasing the precursor substance of beta-balsamic alcohol synthase, promoting the synthesis of glycyrrhetinic acid from beta-balsamic alcohol through 11-beta-balsamic alcohol and 30-hydroxyl-11-oxidosinol, so that the yarrowia lipolytica engineering bacteria constructed can generate a glycyrrhetinic acid product with high added value product by taking cheap glucose as the substrate, and has high yield and simple fermentation process.
The invention has the beneficial effects that:
the invention firstly utilizes yarrowia lipolytica as a chassis bacterium, utilizes high-flux acetyl coenzyme A of the glycyrrhetinic acid, and further reconstructs and integrates a glycyrrhetinic acid biosynthesis module through a metabolic pathway to construct the obtained glycyrrhetinic acid biosynthesis strain, which can be used for producing the glycyrrhetinic acid with high yield by taking glucose as a substrate. The strain uses yarrowia lipolytica for the first time to produce the glycyrrhetinic acid from the head, and the constructed yarrowia lipolytica can generate the glycyrrhetinic acid with the yield of 7 g/L.
The biosynthesis process of the invention is friendly to human body and environment, does not need to utilize a chemical method with complicated operation, and is beneficial to large-scale industrial production of glycyrrhetinic acid.
Drawings
FIG. 1 is a table of modifications of yarrowia lipolytica strains;
FIG. 2 shows the batch fermentation of yarrowia lipolytica engineered bacteria to produce glycyrrhetinic acid;
FIG. 3 is a schematic illustration of the metabolism of glycyrrhetinic acid produced by engineered yarrowia lipolytica.
The specific implementation mode is as follows:
example 1 construction of yarrowia lipolytica engineering bacteria producing Glycyrrhetinic acid
(1) Synthesis of coding sequence of glycyrrhetinic acid synthesis related protein
Artificially synthesizing beta-amyrin synthase bAS, wherein the nucleotide sequence is shown in SEQ ID NO. 001, and the amino acid sequence is shown in SEQ ID NO. 002, and constructing a pUC19 plasmid vector skeleton to obtain a pUC19-bAS plasmid; artificially synthesizing an NADPH-cytochrome P450 reductase gene CPR, wherein the nucleotide sequence is shown in SEQ ID NO. 003, the amino acid sequence is shown in SEQ ID NO. 004, and constructing the CPR to a pUC19 vector skeleton to obtain a pUC19-CRP plasmid; artificially synthesizing cytochrome P450 oxidase CYP88D6 gene, wherein the nucleotide sequence is shown in SEQ ID NO:005, and the amino acid sequence is shown in SEQ ID NO:006, constructing the cytochrome P450 oxidase CYP88D6 gene into a pUC19 vector skeleton, and obtaining a pUC19-CYP88D6 plasmid; artificially synthesizing 11/30-oxidation-beta-balsamic alcohol synthase gene CYP72A154, the nucleotide sequence of which is shown in SEQ ID NO. 007, and the amino acid sequence of which is shown in SEQ ID NO. 008, and obtaining pUC19-CYP72A 154.
(2) Construction of expression module plasmid integrating glycyrrhetinic acid biosynthesis
Constructing a beta-Amyrin synthse expression module, using PmeI-bAS-up and BamHI-bAS-down as primers and pUC19-bAS plasmid as a template, and amplifying to obtain a PCR fragment containing a PmeI enzyme cutting site, a beta-Amyrin synthase gene and a BamHI enzyme cutting site; the pINA1269 plasmid is subjected to double enzyme digestion by PmeI and BamHI, and the two ends of the obtained vector skeleton have PmeI and BamHI cleavage sites. The PCR fragment carrying the PmeI and BamHI enzyme cutting sites is enzymatically connected with a carrier skeleton, and is transferred into an escherichia coli transformant to obtain a correct positive transformant plasmid, and the obtained integrated plasmid is named pINA1269-Php4d-bAS-xpr2 plasmid.
Construction of cytochrome P450 oxidase 88D6(CYP88D6) expression Module Using PEXP1-up/PEXP1Down and lip2t-up/lip2t-down as primers and yarrowia lipolytica genome as a template respectively amplify the fragments of a PEXP1 promoter and a lip2t terminator; CYP88D6-up/down is used as a primer, pUC19-CYP88D6 plasmid is used as a template, a fragment III containing cytochrome P450 oxidase gene CYP88D6 is obtained through amplification, PmeI-PEXE1-up and ClaI-lip2t-down are used as primers, and the three fragments are used as templates to obtain a fragment IV containing a PmeI enzyme cutting site, a PEXE1 promoter, a CYP88D6 gene, a lip2t terminator and a ClaI enzyme cutting site through amplification. PmeI and ClaI enzymes are used for carrying out double enzyme digestion on pINA1269 plasmid to obtain a linear vector fragment V, the vector fragment and the IV fragment are transferred into escherichia coli after enzyme digestion, a correct positive transformant is obtained, plasmid is extracted, and the obtained integrative plasmid is named pINA1269-PEXP1-CYP88D6-lip2t。
Constructing an 11/30-oxidation-beta-balsamic alcohol synthase gene CYP72A154 expression module, and respectively amplifying a PGPD2 promoter and a migt terminator by using pGPD2-up/PGPD2-down and migt-up/migt-down as primers and yarrowia lipolytica genome as a templateTwo fragments of (a); CYP72A154-up/down is used as a primer, and pUC19-CYP72A154 plasmid is used as a template, so that the CYP72A154 fragment is obtained through amplification. PmeI-PGPD2-up/ClaI-migt is used as a primer, the three fragments are used as templates, a fragment containing a PmeI enzyme cutting site, a PGPD2 promoter, a CYP72A154 gene, a migt terminator and a claI enzyme cutting site is obtained by amplification, and the integrated plasmid named pINA1269-P is obtained by connecting the fragment and a linear carrier fragment in the same enzyme cutting and enzyme connecting modeGPD2-CYP72A154-migt。
Constructing a cell P450 reductase CPR expression module, using pTEF-up/down and natr-up/down as primers and yarrowia lipolytica genome as a template, and amplifying to obtain a pTEF promoter fragment and a natr terminator fragment; and amplifying to obtain Cpr gene segment with Cpr-up/down as primer and pUC19-Cpr plasmid as template. PmeI-PTEF-up/ClaI-natr0down is used as a primer, the three fragments are used as a template, a fragment containing a PmeI enzyme cutting site, a PTEF promoter, a Cpr gene, a natr terminator and a claI enzyme cutting site is obtained through amplification, and the fragment and a linear carrier fragment are connected IN the same enzyme cutting enzyme connection mode to form IN1269-PTEF-Cpr-natr integrative plasmid.
To construct the resulting Php4d-bAS-xpr2、PEXP1-CYP88D6-lip2t、PGPD2CYP72A154-migt and-PTEFthe-Cpr-natr is integrated into the pINA1269 plasmid, and the resulting plasmid is named pINA1269-bAS-88D6-Cpr-72A 154.
(3) Construction of yarrowia lipolytica engineering bacterium for producing glycyrrhetinic acid
The pINA1269-bAS-88D6-Cpr-72A154 integrated plasmid obtained in the last step is cut by NotI enzyme to obtain the plasmid carrying pINA1269-Php4d-bAS-xpr2、PEXP1-CYP88D6-lip2t、PGPD2CYP72A154-migt and PTEF-a linear plasmid vector of the Cpr-natr expression cassette, the linear vector carrying these 4 expression cassettes being integrated into the pBR site in yarrowia lipolytica YL-003 strain by the lithium acetate method. The YL-003 strain is obtained by genetic engineering on the basis of the po1f strain, the po1f strain can be obtained by purchasing, and the specific genetic engineering genotype of the YL-003 strain is that the ku70 and ku80 sites are knocked out on the basis of the po1f strain. Specific method for lithium acetate conversionThe method comprises the following steps:
the lithium acetate conversion method comprises the following steps: starting yarrowia lipolytica was cultured in 2ml YPD medium for 18 hours, and 200ul of the cultured yarrowia lipolytica was added to fresh YPD medium and cultured for 4-5 hours. Centrifuging at 6000rpm at room temperature for 5min, collecting thallus, and sterilizing with ddH2And O, re-suspending the bacteria, then centrifuging again to collect the bacteria, and discarding the supernatant. Then 1mL of 100mM lithium acetate precooled at 4 ℃ is added into the centrifuged thallus, after standing treatment for 5min at room temperature, the thallus is centrifuged and collected at 6000rpm at normal temperature, and the preparation of the yarrowia lipolytica competent cell is completed. The transformation mix system included (1)240ul PEG (50% W/v); (2)36ul of 1.0M lithium acetate solution; (3)10ul salmon sperm ss-DNA; (4) the linearized vector-integrated fragments were added in equal amounts of about 400ng each; (5) sterile water is filled to 360 ul. Adding the above into competent cells sequentially, vortex and shake for 1min, water bath at 30 deg.C for 30min, water bath at 42 deg.C for 30min, and centrifuging at 6000rpm for 5 min. After removing the supernatant, 1ml of YPD medium was added and cultured at 30 ℃ and 200rpm for 2 hours to recover the cells. And then centrifuging at 6000rpm for 5min, removing supernatant, washing the thalli for 2 times by using sterile water, finally resuspending by using 100ul of sterile water, coating and screening in an SD solid culture medium lacking leucine, wherein the screening condition is 30 ℃, and performing genome extraction verification on a single colony on a plate after culturing for 48h, wherein the yarrowia lipolytica strain correctly integrating the glycyrrhetinic acid synthesis way is named as GA 001.
Example 2 fermentation and detection of Glycyrrhetinic acid
(1) And (3) shaking flask fermentation: the YPD medium is used for the culture and fermentation of yarrowia lipolytica, for single fermentation in a shake flask, a single clone of GA001 strain is picked from a plate, inoculated into 10mL of YPD medium for activating seed liquid, then the activated seed liquid is transferred to a 250mL shake flask to be loaded with 30mL of YPD medium, and the shake culture is carried out for 4 days under the conditions of 30 ℃ shaking table and 220 rpm. All shake flask fermentation experiments were set up in 3 parallel experimental groups. After the fermentation is finished, detecting the product according to the mode shown in example 2 (2);
(2) centrifuging the cells at 6000rpm for 10min, separating supernatant and thallus, adding 4ml 1-butanol and quartz sand into the thallus, vortex oscillating for 20min, and extracting intracellular product. The butanol was evaporated and the residue was dissolved in methanol and detected by LC-MS after passage through a membrane.
Detection conditions are as follows: the extracted metabolites were detected using an ACQUITY UPLC/MS system (Waters, Milford, MA, USA) with an ACQUITY UPLC HSS C18 column (2.1X 150mm column and 2.1X 5mm VanGuard pre-column; particle size, 1.8 μm, Waters, Milford, MA, USA) and an ACQUITY TQ detector (Waters) [ using electrospray ionisation anion mode with Selective Ion Monitoring (SIM) ]. The mobile phase consisted of 0.025% (v/v) aqueous acetic acid (solvent 1) and 0.025% (v/v) acetonitrile acetate (solvent 2). The sample was separated by gradient elution (elution with 30% solvent 2 for 6 minutes followed by increasing solvent concentration with time, after 22 minutes the concentration reached 100%: 40% at 6 minutes, 50% at 18 minutes and 100% at 28 minutes) at a flow rate of 0.20 mL/min. The final conditions were maintained for 3.5 minutes and then returned to the initial conditions, resulting in a total chromatographic run time of 38.5 minutes. The sample management conditions and the column were maintained at 15 ℃ and 30 ℃ respectively. For MS detection, the capillary voltage was set to 2.5kV, the cone voltage was set to 80V, the extraction cone voltage was set to 3V, the source temperature was set to 150 ℃, the desolvation temperature was set to 350 ℃, the cone gas flow rate was set to 50L/h and the desolvation gas flow rate was set to 600L/h, respectively. The amount of the extracted target compound in the peak area was determined using MassLynx software (Waters).
(3) The GA001 strain was cultured in the fermentation manner described above, and a glycyrrhetinic acid production of 53.2mg/L was finally detected.
Example 3 attenuation of lanosterol synthase and enhancement of squalene synthase and squalene epoxidase expression Acid yield
(1) Construction of expression modules for squalene synthase (ERG9) and squalene epoxidase (ERG1)
Construction of the Php4d-ERG9-xpr2 expression Module: respectively amplifying to obtain a Php4d promoter and a xpr2t terminator by using hp4d-up/down and xpr2t-up/down as primers and a pINA1269 plasmid as a template; the gene of squalene synthase ERG9 is obtained by amplification by taking ERG9-F/R as a primer and yarrowia lipolytica genome as a template, and the expression module Php4d-ERG9-xpr2 is obtained by constructing by using an Overlap method.
Construction of the pTEFin-ERG1-lip2t expression Module: amplifying to obtain a PTEFin promoter and a lip2t terminator by taking pTEFin-up/down and lip2t-up/down as primers and pMT015 plasmid as a template; the gene of squalene epoxidase ERG1 is amplified by taking ERG1-F/R as a primer and yarrowia lipolytica genome as a template, and the pTEFin-ERG1-lip2t expression module is constructed by utilizing an Overlap method. Wherein the sequence of the pTEFin promoter is shown in SEQ ID No. 009.
The two expression modules were assembled by the Gibson assembly method to obtain a plasmid of pUC19-ERG9-ERG1 expression cluster.
(2) Expression of ERG9 and ERG1 genes at lanosterol synthase (ERG7) site
Using del-ERG7-1-up/del-ERG7-1-down as primer and yarrowia lipolytica genome as template to amplify to obtain segment of 500bp upstream of ERG7 gene; using HisG-F/R as a primer and pUC19-HisG-Ura-HisG plasmid as a template, and amplifying to obtain a HisG-Ura-HisG uracil screening marker loss module; using hp4d-up-hisG/lip2t as a primer and pUC19-ERG9-ERG1 as a plasmid, and amplifying to obtain an ERG9-ERG1 expression module gene cluster; and (3) amplifying by taking del-ERG7-2-up/del-ERG7-2-down as a primer and yarrowia lipolytica genome as a template to obtain a 500bp fragment at the downstream of the ERG7 gene. The transformation of the gene expression module is carried out by adopting a yeast self-assembly mode, the length of homologous fragments of two adjacent fragments is about 80bp, the transformation method refers to a lithium acetate transformation method described in example 1, the transformed strain is YL-003, the addition amount of each fragment is 400ng, an SD-delta Ura plate is coated with the incubated bacterial liquid, and the engineering bacteria YL-103-Ura which excessively express squalene synthase (ERG9) and squalene epoxidase (ERG1) at the ERG7 site are obtained by screening.
(3) Loss of URA selection marker
The YL-103-Ura strain simultaneously carries a uracil loss module HisG, Ura and His, and can screen a marker gene through 5-fluoroorotic acid loss Ura, and the specific operation steps are as follows: screening the positive monoclone obtained in the last step to 10ml of YPD culture medium, culturing overnight for 16h, properly diluting, coating 100ul of 5-fluoroorotic acid YPD plate with the final concentration of 1mg/ml, culturing at 30 ℃ for 2-3 days, selecting 30 larger monoclonals, simultaneously streaking on an SD plate and an SD-delta Ura plate respectively, continuously placing in an incubator at 30 ℃ for standing and culturing for 2-3 days, selecting bacterial colonies growing on the SD plate and not growing on the SD-delta Ura plate according to the growth conditions of the two plates, and obtaining the engineering bacteria successfully losing the Ura screening marker, wherein the bacterial strain is named as YL-103.
Example 4 regulated expression of mevalonate pathway Key enzymes (HMGS and trHMGR)
FBA1in-up/down is used as a primer, pRFBA1in plasmid is used as a template, and the FBA1in promoter is obtained through amplification; using HMGS-F/R as a primer and yarrowia lipolytica genome as a template to amplify to obtain a hydroxymethyl glutarate-CoA synthase (HMGS) gene segment; and (3) amplifying by using the natR-up/down as a primer and using the yarrowia lipolytica genome as a template to obtain the natR terminator. And assembling the obtained 3 fragments in an Overlap mode to construct and obtain a Pfbain-HMGS-natR expression module.
Using hp4d-up/down as a primer and pINA1269 plasmid as a template to amplify to obtain an hp4d promoter; using trHMGR-F/R as a primer and yarrowia lipolytica genome as a template, and amplifying to obtain a gene fragment with 500 amino acids truncated by hydroxymethyl glutarate reductase; and (3) amplifying by using xpr2t-up/down as a primer and pINA1269 plasmid as a template to obtain a xpr2t terminator. The 3 fragments obtained were assembled by means of Overlap to construct an expression module of Php4d-trHMGR-xpr2 t.
And constructing the PFBA1in-HMGS-natR expression module and the expression module of Php4d-trHMGR-xpr2t on a pUC19 plasmid in a Gibson assembly mode to obtain the pUC19-HMGS-trHMGR plasmid. Wherein the promoter sequence of FBA1in is shown in SEQ ID NO: 010.
And constructing a Pfbain-HMGS-natR expression module and an expression module of Php4d-trHMGR-xpr2t on a pUC19 plasmid in a Gibson assembly mode to obtain the pUC19-HMGS-trHMGR plasmid.
(1) Regulated expression of HMGS and trHMGR
Using del-poxB1-up/down as primer and yarrowia lipolytica genome as template to amplify to obtain poxB gene upstream 500bp segment; using HisG-up/down as a primer and pUC19-HisG-URA-HisG plasmid as a template, and amplifying to obtain a screening marker Ura loss module; amplifying to obtain regulated HMGS and trHMGR gene expression clusters by using fba1-1/xpr2t-2 as a primer and pUC19-HMGS-trHMGR plasmid as a template; using del-poxB2-up/down as primer and yarrowia lipolytica genome as template to amplify and obtain the downstream 500bp segment of poxB gene.
The transformation of the gene expression module adopts a yeast self-assembly mode, the homologous arm between adjacent modules is about 80bp, the transformation mode refers to example 3(2), the transformed strain is the YL103 strain constructed in example 3, the SD-delta Ura plate is coated with the transformation liquid, and the grown positive clone is verified to be correctly named as YL-108-Ura.
(2) Recovery of YL-108-Ura screening tags
The YL108-108-Ura was screened for marker loss according to the method of example 3(3), and the strain lacking the Ura screening marker was designated YL-108.
(4) Integration of Glycyrrhetinic acid biosynthesis Gene Module
According to the integration type plasmid pINA1269-bAS-88D6-Cpr-72A154 of the glycyrrhetinic acid biosynthesis gene cluster constructed in example 1(3), the glycyrrhetinic acid biosynthesis integration gene cluster is integrated into the pBR site of the YL-108 strain according to the lithium acetate transformation method of yarrowia lipolytica, and thus the engineered strain GA-106 capable of biosynthesizing glycyrrhetinic acid yeast is obtained.
(5) Evaluation of fermentation of GA-106 Strain
The fermentation evaluation of the yarrowia lipolytica engineered strain producing glycyrrhetinic acid was carried out in the same manner as in example 2, and it was confirmed that the production amount of glycyrrhetinic acid was 175.5 mg/L.
Example 5 multicopy integration of Glycyrrhetinic acid Synthesis Gene Cluster
(1) Construction of multicopy integration plasmid pINA1292-bAS-88D6-Cpr-72A154
According to P in example 1hp4d-bAS-xpr2、PEXP1-CYP88D6-lip2t、PGPD2CYP72A154-migt and-PTEFIntegrating each gene expression module into pINA1292 plasmid by using Gibson assembly mode to construct glycyrrhetinic acid biosynthesis multi-copy completeThe synthetic plasmid pINA1292-bAS-88D6-Cpr-72A 154.
(2) Multicopy integration of glycyrrhetinic acid heterologous pathway enzymes
And (3) carrying out enzyme digestion on the multicopy integration plasmid pINA1292-bAS-88D6-Cpr-72A154 obtained in the last step by using NotI enzyme to obtain a linearized pINA1292-bAS-88D6-Cpr-72A154 fragment, integrating the fragment into an YL-108 strain by a lithium acetate conversion method, coating an SD-delta Leu plate on the incubated bacterial liquid, and screening the positive clone obtained by growth on the plate to obtain a GA 205.
(3) Evaluation of fermentation of GA205 Strain
The GA205 strain was subjected to fermentation evaluation in the same manner as in example 2, and the production of glycyrrhetinic acid at 240.3mg/L was examined.
Example 6 integration of cytochrome b5
(1) Construction of cytochrome b5 expression cassette
GPDin-up/down is taken as a primer, a synthesized GPDin sequence is taken as a template, and a GPDin promoter is obtained by amplification, wherein the GPDin promoter sequence is shown in SEQ ID NO: 011; using CYB5-up/down as a primer and synthesized cytochrome b5 as a template to amplify to obtain a cytochrome b5 gene, wherein the nucleotide sequence of the cytochrome b5 is shown in SEQ ID NO:012, and the amino acid sequence is shown in SEQ ID NO: 013; cyc1-up/down is used as a primer, pCFB153 plasmid is used as a template, and Cyc terminator is obtained by amplification. The three fragments are assembled by using an Overlap method to construct an expression module of the PGPDin-CYB5-Cyc gene.
(2) Integration of cellular b5 Synthesis Module
D17-up1/down1 is used as a primer to amplify to obtain a homologous fragment of 500bp at the upstream of the D17 gene; using HisG-up/down as a primer and pUC19HisG-Ura-HisG as a template to obtain a HisG-Ura-HisG screening marker recovery module through amplification; amplifying to obtain a PGPDin-CYB5-Cyc gene expression module by taking PGPDin-up/Cyc-down as a primer and the expression module as a template; d17-up2/down2 is used as a primer to amplify to obtain a homologous fragment of 500bp at the downstream of the D17 gene. The homologous fragments were integrated into GA205 strain by lithium acetate integration using yeast self-assembly, and the resulting incubation fluid was applied to SD-. DELTA.Ura plates and positive clones grown on the plates were selected. The correct strain was glycyrrhetinic acid-producing strain GA208, which incorporated cytochrome b 5.
(3) Fermentation plate of GA208 strain
The GA208 strain was subjected to fermentation evaluation in the same manner as in example 2, and the production of glycyrrhetinic acid at 290.4mg/L was detected.
The above description: integrating glycyrrhetinic acid biosynthesis modules b-AS, CYP88D6, CYA72A154 and CPR into yarrowia lipolytica Chassis bacteria through tool plasmids to construct and obtain a glycyrrhetinic acid biosynthesis primary strain GA001, wherein the strain integrated with the glycyrrhetinic acid biosynthesis modules has the capacity of catalyzing glucose to generate glycyrrhetinic acid through conventional shake flask fermentation verification; starting from a strain which does not integrate a glycyrrhetinic acid biosynthesis module, the synthesis of 2, 3-oxidosqualene is increased by knocking out lanosterol synthase and overexpressing squalene oxidase and squalene epoxidase at the site; enhancing the MVA pathway by integrating a strong promoter-expressing trHMGR and HMGS enzyme at the poxB site; integrating a plurality of glycyrrhetinic acid biosynthesis modules by integrating the glycyrrhetinic acid biosynthesis pathway into the engineered yarrowia lipolytica using a multicopy integrative tool plasmid; the over-expression of cytochrome b5 is also realized, and the yield of the modified integrated strains is remarkably improved compared with that of a glycyrrhetinic acid biosynthesis primary strain GA 001; compared with the original strain before modification, the yield of glycyrrhetinic acid is obviously improved, and the effects of the modification means are fully demonstrated.
In the examples, each plasmid was publicly reported and commercially available; the primers involved therein are designed based on the amplification template and the purpose of amplification, in combination with conventional primer design methods.
Example 7 fed-batch fermentation of GA208 Strain to produce Glycyrrhetinic acid
A single GA208 clone was picked from the plate, inoculated into a test tube containing 2ml of YPD medium, cultured with shaking at 30 ℃ and 220rpm for 24 hours, transferred into a 500ml Erlenmeyer flask containing 100ml of YPD medium, and cultured with shaking for 24 hours to obtain a seed solution required for batch fermentation. Transferring 100ml of the seed solution into 3L of fermentation mediumThe components are as follows: 60g/L glucose, 15g/L (NH)4)2SO4，8g/L KH2PO4,6.15g/L MgSO412ml/L vitamin, 10ml/L trace metal salt. Wherein the trace metal salt solution comprises the following components: 5.75g/L ZnSO4*7H2O，0.32g/LMnCI2，0.32g/L CuSO4，0.47g/L CoCl2，0.48g/L Na2MoO4，2.9g/L CaCl2·2H2O，2.8g/LFeSO4*7H2O, 0.5M EDTA. Wherein the vitamin solution comprises the following components: 0.05g/L of biotin, 1g/L of calcium pantothenate, 1g/L of nicotinic acid, 25g/L of inositol, 1g/L of thiamine hydrochloride, 1g/L of pyridoxal phosphate, and 0.2g/L of p-aminobenzoic acid.
The batch fermentation temperature was 30 ℃ and pH was controlled to 6.0 using NaOH, fed-batch glucose was controlled to a concentration of 30g/L and the fermentation process examined the production of product.
The final GA208 strain was fermented to produce 7g/L glycyrrhetinic acid, which is the highest level reported for de novo synthesis of glycyrrhetinic acid at present, as shown in FIG. 2.
Nucleotide and amino acid sequence listing of the specification
< 110 > Hebei Weidakang Biotech Ltd
Less than 120 yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as substrate, construction and application thereof
＜160＞ ３
＜210＞ 1
＜211＞2289bp
＜212＞ DNA
< 213 > is artificially synthesized
＜400＞ 1
atgtggaggc tgaagatagc ggaaggaggg aaggacccat acatatacag cacaaacaac 60
ttcgtgggga ggcagacatg ggagtatgat cccgatggtg ggagtgccga ggagagagct 120
caggttgatg ccgctcgtct ccatttctat aacaaccgct tccaggtcaa gccctgtggc 180
gacctccttt ggcgttttca gattctgaga gaaaataact tcaaacaaac aatagctagc 240
gtgaagatag gagatggaga ggaaataaca tacgaaaagg cgacaacggc ggtgagaagg 300
gctgcacatc acctatccgc attgcagacc agcgatggcc attggcctgc tcaaattgca 360
ggtcctctgt ttttccttcc ccccttggtt ttttgtatgt acattacagg acatcttgat 420
tcggtattcc cagaagagta tcgcaaagag attcttcgtt acatatacta tcaccagaat 480
gaagatggag ggtgggggct acacatagag ggtcacagca ccatgttttg tactgcactc 540
aactatatat gcatgcgaat tcttggagaa gggcccgatg ggggtcaaga caatgcttgt 600
gctagagcaa gaaagtggat tcatgatcat ggtggtgtaa cacatatacc ttcatgggga 660
aaaacttggc tttcgatact tggtgtattt gataggtgcg gaagcaaccc aatgccccct 720
gagttttgga tcctgccttc atttcttcct atgcatccag ctaaaatgtg gtgttattgc 780
cgattggtat acatgcctat gtcttacttg tatgggaaaa ggtttgtggg tccaatcaca 840
ccactcattc tacagttgag agaagaactc tttactgaac cttatgaaaa agttaattgg 900
aagaaagcac gtcaccaatg tgcaaaggaa gatctttact atccccatcc tttgttacaa 960
gatctgatat gggatagttt atgcttattc actgagccac ttctgactcg ttggcctttc 1020
aacaagctgg ttagagaaaa ggcccttcaa gtaacaatga agcatatcca ctatgaagat 1080
gagactagtc gatacataac cattgggtgt gtggaaaagg ttttatgtat gcttgcttgt 1140
tgggtggaag atccaaatgg agatgctttc aagaagcatc ttgcaagggt cccggattac 1200
ttatgggttt cggaagatgg aatgaccatg cagagttttg gtagtcaaga atgggatgct 1260
ggttttgccg ttcaagcttt gcttgccact aacctagtcg aggaaattgc tcccacactt 1320
gccaaaggac atgatttcat caagaaatct caggttaggg acaacccttc aggagatttt 1380
aagagcatgt atcgtcatgt ttctaaaggc tcatggacct tctccgatca agaccatgga 1440
tggcaagttt ctgattgcac agcagaaggt ttgaagtgtt gtctactttt atcaatgttg 1500
cctccagaga ttgtggggga aaagatggaa cctgaaaggt tatatgattc agtcaatgtc 1560
ctattgtcgc ttcagagtaa aaagggtggt ttatcagcgt gggagccagc aggagctcaa 1620
gaatggttag aactactcaa tcccacggaa ttttttgcgg acattgtagt tgagcatgaa 1680
tacgttgagt gcactggatc agcaattcag gcactagttc tgttcaagaa gctatatcca 1740
gggcatagga agaaagagat agagaatttc attgccaatg cagttcgatt ccttgaagat 1800
acacaaacag ctgatggttc atggtatgga aattggggag tttgcttcac ttacggttct 1860
tggttcgcac ttggtggtct tgcagctgct ggcaagactt ttgccaattg tgctgctatt 1920
cgcaaagctg ttaaatttct tctcacaaca cagagagagg atggtggatg gggggagagc 1980
tatctttcaa gcccaaaaaa gatatatgta cctcttgaag gaagtcgatc aaatgttgta 2040
catactgcat gggcccttat gggtttaatt catgctggcc aggcagagag agaccctgct 2100
cctcttcacc gagctgcaaa attgatcatc aattcccaat tggaagaggg tgattggccc 2160
caacaggaaa tcacgggagt attcatgaaa aattgtatgc tgcattaccc aatgtataga 2220
gatatttatc caatgtgggc tctagctgag tatcgtagac gggttccatt gccttccact 2280
ccagcttaa 2289
＜210＞ 2
＜211＞762
＜212＞ PRT
< 213 > is artificially synthesized
＜400＞ 1
MWRLKIAEGG KDPYIYSTNN FVGRQTWEYD PDGGSAEERA QVDAARLHFY NNRFQVKPCG 60
DLLWRFQILR ENNFKQTIAS VKIGDGEEIT YEKATTAVRR AAHHLSALQT SDGHWPAQIA 120
GPLFFLPPLV FCMYITGHLD SVFPEEYRKE ILRYIYYHQN EDGGWGLHIE GHSTMFCTAL 180
NYICMRILGE GPDGGQDNAC ARARKWIHDH GGVTHIPSWG KTWLSILGVF DRCGSNPMPP 240
EFWILPSFLP MHPAKMWCYC RLVYMPMSYL YGKRFVGPIT PLILQLREEL FTEPYEKVNW 300
KKARHQCAKE DLYYPHPLLQ DLIWDSLCLF TEPLLTRWPF NKLVREKALQ VTMKHIHYED 360
ETSRYITIGC VEKVLCMLAC WVEDPNGDAF KKHLARVPDY LWVSEDGMTM QSFGSQEWDA 420
GFAVQALLAT NLVEEIAPTL AKGHDFIKKS QVRDNPSGDF KSMYRHVSKG SWTFSDQDHG 480
WQVSDCTAEG LKCCLLLSML PPEIVGEKME PERLYDSVNV LLSLQSKKGG LSAWEPAGAQ 540
EWLELLNPTE FFADIVVEHE YVECTGSAIQ ALVLFKKLYP GHRKKEIENF IANAVRFLED 600
TQTADGSWYG NWGVCFTYGS WFALGGLAAA GKTFANCAAI RKAVKFLLTT QREDGGWGES 660
YLSSPKKIYV PLEGSRSNVV HTAWALMGLI HAGQAERDPA PLHRAAKLII NSQLEEGDWP 720
QQEITGVFMK NCMLHYPMYR DIYPMWALAE YRRRVPLPST PA 762
＜210＞ 3
＜211＞1989bp
＜212＞ DNA
< 213 > is artificially synthesized
＜400＞ 1
atgtgctgca gacatcctag gtcagttggt ggaactagtg ctgcgcctga aactccccaa 60
agttccgctc ccgcaacacc attgcctgct ccagctccaa cagttcctac gcccgcccct 120
cctactccag catcaacaac agaagctcct gcaccctcta ccccagcttc aactaccggc 180
gcaccaagca ctcctgcttc cacaactggt gccccgagta cccccgcatc aacaacggga 240
agttcagatc aaacccaatt cctagctaac ttattggttc aattgcaagc agccggggca 300
ggtccagaac aacttcaacc aattgtggat gccattgcta agcagttcgt tcaacaacag 360
caacaatctc aagctgtgcc cgatccgcaa caagccgttg atgaaatttg tattgaacta 420
ggagcatctc cggattacac tacccaggtg gctcaaatat tagaacaagg acacgaccct 480
aacagcgctt ctggatctag atccttacaa cctccaccac caccatctgg ttctaatcct 540
ggcggtggga atagtggcca agaagtccct gaacccaagc aaaagaaggc cagagcgccc 600
aaaaaacaag gtagcgaaat ggaaactgat attactacta tggcagctgc tgcggacttt 660
aaactggacg atttcgtgac cacttgggtt ggagcctgta ctacagctga aggtaaggct 720
atggttacca ctatagaatt gttaggtcat tccataatca tgagtgtagg tgttctgttc 780
atgttcgtca aaccgcaaca atactcaaac gcacatgatc ctagattgga gccgttgcag 840
agtcagtccg aattaattaa gatgataaat gcatcctcaa tgggaatggc tgaaatcagg 900
aaggaattgc aagctaaaca aaaaacatta acaattgaag ccttgcaaac aattctgagg 960
aaagccatgc attacaaagg tgtttgggtt tgcattggta tttcatttgg atttactagt 1020
cttggcaaag gtatggaatt cagagggaga tggggcatca atggtcaatc tccaaccgct 1080
tccgcagccc cattcgttga agcttacaag caacactcaa aagtagctgc aaatttgaat 1140
gaggacagta tggatttggt tgagttctgg aataaagcta ggttcgaaga ttggggtgcg 1200
agaacaactc aatgtaaagc aggtgctatg aggaagagga atatgttgat tataagttgg 1260
agtccattaa cctcttcaaa agaatcaatg tatgggaaat acccattttg tgttataaga 1320
tcagactatt tccactatct tggtgatgag aacgttacat tgtctcattt gcaggaagac 1380
ttggttaaaa gtctaaatct gtgcgctgac agaacaaacg ggttaaatgc cacattacat 1440
gtgtgtgccg gtaagggcga ctggaaatgg agacatgaat ggttacaaca gtccaggttc 1500
tatggtagag tgacccacgg ttcaaatggg atctgtcaga gatgcttcgc tgcaaaaaat 1560
gactggttgg acgttcacga aagattcaac aacgctgaag acgtactgcg tgcacaagct 1620
accgcagtag gggaaggcat agccatgaaa caactgtccg gctggacacc taatatggaa 1680
cttccagact tattacattg tatctggcta ggtacgggaa gagatttggt cggtagtttg 1740
tgcatggaaa tggctgaaac aagacaagat ttggtgggtt ctacctatga tgagagactg 1800
gactgtttga gaagggatat tcaagcatgg tgcgcaagtc atgggattag accgagcact 1860
attgatgaat tatctctagc caagctgggt gttgaaaccc tatctcttga ttttccacaa 1920
ggaccatcaa aaggatacgc caataaagtt ttgcaattga gacttattta ctttaacggc 1980
gcttgttaa 1989
＜210＞ 4
＜211＞662
＜212＞ PRT
< 213 > is artificially synthesized
＜400＞ 1
MCCRHPRSVG GTSAAPETPQ SSAPATPLPA PAPTVPTPAP PTPASTTEAP APSTPASTTG 60
APSTPASTTG APSTPASTTG SSDQTQFLAN LLVQLQAAGA GPEQLQPIVD AIAKQFVQQQ 120
QQSQAVPDPQ QAVDEICIEL GASPDYTTQV AQILEQGHDP NSASGSRSLQ PPPPPSGSNP 180
GGGNSGQEVP EPKQKKARAP KKQGSEMETD ITTMAAAADF KLDDFVTTWV GACTTAEGKA 240
MVTTIELLGH SIIMSVGVLF MFVKPQQYSN AHDPRLEPLQ SQSELIKMIN ASSMGMAEIR 300
KELQAKQKTL TIEALQTILR KAMHYKGVWV CIGISFGFTS LGKGMEFRGR WGINGQSPTA 360
SAAPFVEAYK QHSKVAANLN EDSMDLVEFW NKARFEDWGA RTTQCKAGAM RKRNMLIISW 420
SPLTSSKESM YGKYPFCVIR SDYFHYLGDE NVTLSHLQED LVKSLNLCAD RTNGLNATLH 480
VCAGKGDWKW RHEWLQQSRF YGRVTHGSNG ICQRCFAAKN DWLDVHERFN NAEDVLRAQA 540
TAVGEGIAMK QLSGWTPNME LPDLLHCIWL GTGRDLVGSL CMEMAETRQD LVGSTYDERL 600
DCLRRDIQAW CASHGIRPST IDELSLAKLG VETLSLDFPQ GPSKGYANKV LQLRLIYFNG 660
AC 662
＜210＞ 5
＜211＞1482 bp
＜212＞ DNA
< 213 > is artificially synthesized
＜400＞ 1
atggaagttc attgggtttg tatgtcagct gcaactttgt tggtttgtta catcttcggt 60
tctaagttcg ttagaaattt gaacggttgg tactacgatg ttaagttgag aagaaaggaa 120
catccattac caccaggtga catgggttgg ccattaattg gtgacttgtt gtcttttatt 180
aaggatttct cttcaggtca tccagattct tttattaaca atttggtttt gaagtacggt 240
agatcaggta tctataagac tcatttgttc ggtaacccat ctatcatcgt ttgtgaacca 300
caaatgtgta gaagagtttt gacagatgat gttaacttca agttgggtta cccaaagtct 360
attaaagaat tggctagatg tagaccaatg attgatgttt caaacgcaga acatagattg 420
tttagaagat taatcacatc tccaatcgtt ggtcataaag ctttagcaat gtacttggaa 480
agattggaag aaatcgttat taattcattg gaagaattgt cttcaatgaa gcatccagtt 540
gaattgttga aggaaatgaa gaaagtttct tttaaagcta tcgttcatgt ttttatgggt 600
tcttcaaacc aagatattat taagaaaatt ggttcttctt ttactgattt gtacaacggc 660
atgttctcta tcccaattaa tgttccaggt tttacattcc ataaagcttt ggaagcaaga 720
aagaaattgg ctaagatcgt tcaaccagtt gttgatgaaa gaagattaat gatcgaaaat 780
ggtccacaag aaggttcaca aagaaaggat ttgatcgata tcttgttaga agttaaagat 840
gaaaatggta gaaaattaga agatgaagat atttctgatt tgttaattgg tttgttattt 900
gctggtcatg aatctactgc aacatcattg atgtggtcta tcacttactt aacacaacat 960
ccacatatct tgaagaaagc taaggaagaa caagaagaaa tcactagaac aagattttct 1020
tcacaaaaac aattgtcatt gaaggaaatt aaacaaatgg tttatttgtc tcaagttatt 1080
gatgaaactt tgagatgtgc aaacattgct tttgcaactt ttagagaagc tacagcagat 1140
gttaacatca acggttacat catcccaaaa ggttggagag ttttgatttg ggctagagca 1200
atccatatgg attcagaata ctacccaaat ccagaagagt ttaatccatc tagatgggat 1260
gattacaatg ctaaagcagg tacattttta ccatttggtg ctggttcaag attgtgtcca 1320
ggtgctgatt tggcaaagtt ggaaatctct attttcttgc attacttttt gttaaattac 1380
agattggaaa gaattaatcc agaatgtcat gttacttcat taccagtttc taaaccaaca 1440
gataactgtt tggctaaagt tattaaagtt tcttgtgcat aa 1482
＜210＞ 6
＜211＞ 493
＜212＞ PRT
< 213 > is artificially synthesized
＜400＞ 1
MEVHWVCMSA ATLLVCYIFG SKFVRNLNGW YYDVKLRRKE HPLPPGDMGW PLIGDLLSFI 60
KDFSSGHPDS FINNLVLKYG RSGIYKTHLF GNPSIIVCEP QMCRRVLTDD VNFKLGYPKS 120
IKELARCRPM IDVSNAEHRL FRRLITSPIV GHKALAMYLE RLEEIVINSL EELSSMKHPV 180
ELLKEMKKVS FKAIVHVFMG SSNQDIIKKI GSSFTDLYNG MFSIPINVPG FTFHKALEAR 240
KKLAKIVQPV VDERRLMIEN GPQEGSQRKD LIDILLEVKD ENGRKLEDED ISDLLIGLLF 300
AGHESTATSL MWSITYLTQH PHILKKAKEE QEEITRTRFS SQKQLSLKEI KQMVYLSQVI 360
DETLRCANIA FATFREATAD VNINGYIIPK GWRVLIWARA IHMDSEYYPN PEEFNPSRWD 420
DYNAKAGTFL PFGAGSRLCP GADLAKLEIS IFLHYFLRNY RLERINPECH VTSLPVSKPT 480
DNCLAKVIKV SCA 493
＜210＞ 7
＜211＞1437 bp
＜212＞ DNA
< 213 > is artificially synthesized
＜400＞ 1
atggctgcaa cagctgctct tagaccattt gatagtgttc catcattggg taaagctttt 60
gctttcttcg ctaggaataa attatgtaag gaactaatgc aaaaaggtag tgaacacccc 120
agaatgttca gaatgcatgt cggaccacaa accgcgtgcg tcgtaacaca tccagaatta 180
gctagaagcg ttctgacacg tccaaaggat tttataaagt ttcaagtacc tcgtaaccca 240
gcgtcagcat tagactcttt gttaaacaga tctaaagacg gaaccttaag ccttttgatg 300
tctaatggtc atgattgggc ttcccaaagg aagccagtgg atcccgcttt tgagaaacaa 360
gcattacgta atttactacc aaaattcaat gattgtagcg cgagactact ggagacctgg 420
cgtggagctg atgaggtgga cgcgaaacag gatatgtcac gtttcgcttt agatgtttta 480
ggttccgcaa tgctgggtca aagctttggt gcaatcgatg gtaccttttc cgatagttat 540
gaatactaca aatatatcat ggtagagcaa aacaatccac tatatatgag cttccccctt 600
atggagagac taccaacatc ccgtaataga agaatgagag aagctgtaca ccatatgcat 660
ggtgtattgc agggtgctat tgacgctaga gtgcagttaa gaaaagacca acaagcggct 720
ggtacattga gtgatgaacc tcaagacatg ctggacatgc ttcttggtcc aggggccgac 780
gttccaactg atggcgtgct gcctaacgcc ggcgctttgc tacccaattt gtggattttt 840
ttcatcgctg gacacgatac tacagcaatt agtttggcat ggttaatgta ttttttggcc 900
aaatatccag aggttcaaca aaaggcacgt gaggaaactc aaaaagtact tgcgggtcgt 960
aaggatccca cctctgaaga tttagataac gttccatatt tatcagccgt tattaacgaa 1020
ggtttaagag ttagacctcc aatattcaat ttgtataccc gtcaagcagc acatgacaca 1080
gaattagatg gagtgttttt gccaaagggt actggcattg cgttgcacat agctgctatt 1140
aataagcatc ctgaagtgtg gggtgaagct gaagatttta atccagaaag gtttctgcaa 1200
gagaaacaac ctcgtgtctt tcataatctg ccattttctg ctggacctag gagatgtcta 1260
ggggacaagt tctctttgat ggaacaaaag tctttattga tgaagttatt gactgagtac 1320
aaggtcttac cacatgagag tactttggat ggtgataaaa attttacctc ttctatgcta 1380
ggtttgatct ttttacaacc tgaagatata aaggtcagat tgcaggcagt acaataa 1437
＜210＞ 8
＜211＞478
＜212＞PRT
< 213 > is artificially synthesized
＜400＞ 1
MAATAALRPF DSVPSLGKAF AFFARNKLCK ELMQKGSEHP RMFRMHVGPQ TACVVTHPEL 60
ARSVLTRPKD FIKFQVPRNP ASALDSLLNR SKDGTLSLLM SNGHDWASQR KPVDPAFEKQ 120
ALRNLLPKFN DCSARLLETW RGADEVDAKQ DMSRFALDVL GSAMLGQSFG AIDGTFSDSY 180
EYYKYIMVEQ NNPLYMSFPL MERLPTSRNR RMREAVHHMH GVLQGAIDAR VQLRKDQQAA 240
GTLSDEPQDM LDMLLGPGAD VPTDGVLPNA GALLPNLWIF FIAGHDTTAI SLAWLMYFLA 300
KYPEVQQKAR EETQKVLAGR KDPTSEDLDN VPYLSAVINE GLRVRPPIFN LYTRQAAHDT 360
ELDGVFLPKG TGIALHIAAI NKHPEVWGEA EDFNPERFLQ EKQPRVFHNL PFSAGPRRCL 420
GDKFSLMEQK SLLMKLLTEY KVLPHESTLD GDKNFTSSML GLIFLQPEDI KVRLQAVQ 478
＜210＞ 9
＜211＞531 bp
＜212＞ DNA
< 213 > is artificially synthesized
＜400＞ 1
agagaccggg ttggcggcgc atttgtgtcc caaaaaacag ccccaattgc cccaattgac 60
cccaaattga cccagtagcg ggcccaaccc cggcgagagc ccccttctcc ccacatatca 120
aacctccccc ggttcccaca cttgccgtta agggcgtagg gtactgcagt ctggaatcta 180
cgcttgttca gactttgtac tagtttcttt gtctggccat ccgggtaacc catgccggac 240
gcaaaataga ctactgaaaa tttttttgct ttgtggttgg gactttagcc aagggtataa 300
aagaccaccg tccccgaatt acctttcctc ttcttttctc tctctccttg tcaactcaca 360
cccgaaatcg ttaagcattt ccttctgagt ataagaatca ttcaaaatgg tgagtttcag 420
aggcagcagc aattgccacg ggctttgagc acacggccgg gtgtggtccc attcccatcg 480
acacaagacg ccacgtcatc cgaccagcac tttttgcagt actaaccgca g 531
＜210＞ 10
＜211＞　1000bp
＜212＞ DNA
< 213 > is artificially synthesized
＜400＞ 1
aacagtgtac gcagtactat agaggaacaa ttgccccgga gaagacggcc aggccgccta 60
gatgacaaat tcaacaactc acagctgact ttctgccatt gccactaggg gggggccttt 120
ttatatggcc aagccaagct ctccacgtcg gttgggctgc acccaacaat aaatgggtag 180
ggttgcacca acaaagggat gggatggggg gtagaagata cgaggataac ggggctcaat 240
ggcacaaata agaacgaata ctgccattaa gactcgtgat ccagcgactg acaccattgc 300
atcatctaag ggcctcaaaa ctacctcgga actgctgcgc tgatctggac accacagagg 360
ttccgagcac tttaggttgc accaaatgtc ccaccaggtg caggcagaaa acgctggaac 420
agcgtgtaca gtttgtctta gcaaaaagtg aaggcgctga ggtcgagcag ggtggtgtga 480
cttgttatag cctttagagc tgcgaaagcg cgtatggatt tggctcatca ggccagattg 540
agggtctgtg gacacatgtc atgttagtgt acttcaatcg ccccctggat atagccccga 600
caataggccg tggcctcatt tttttgcctt ccgcacattt ccattgctcg gtacccacac 660
cttgcttctc ctgcacttgc caaccttaat actggtttac attgaccaac atcttacaag 720
cggggggctt gtctagggta tatataaaca gtggctctcc caatcggttg ccagtctctt 780
ttttcctttc tttccccaca gattcgaaat ctaaactaca catcacacaa tgcctgttac 840
tgacgtcctt aagcgaaagt ccggtgtcat cgtcggcgac gatgtccgag ccgtgagtat 900
ccacgacaag atcagtgtcg agacgacgcg ttttgtgtaa tgacacaatc cgaaagtcgc 960
tagcaacaca cactctctac acaaactaac ccagctctcc 1000
＜210＞ 11
＜211＞　1130bp
＜212＞ DNA
< 213 > is artificially synthesized
＜400＞ 1
gacgcagtag gatgtcctgc acgggtcttt ttgtggggtg tggagaaagg ggtgcttgga 60
gatggaagcc ggtagaaccg ggctgcttgg ggggatttgg ggccgctggg ctccaaagag 120
gggtaggcat ttcgttgggg ttacgtaatt gcggcatttg ggtcctgcgc gcatgtccca 180
ttggtcagaa ttagtccgga taggagactt atcagccaat cacagcgccg gatccacctg 240
taggttgggt tgggtgggag cacccctcca cagagtagag tcaaacagca gcagcaacat 300
gatagttggg ggtgtgcgtg ttaaaggaaa aaaaaagaag cttgggttat attcccgctc 360
tatttagagg ttgcgggata gacgccgacg gagggcaatg gcgccatgga accttgcgga 420
tatcgatacg ccgcggcgga ctgcgtccga accagctcca gcagcgtttt ttccgggcca 480
ttgagccgac tgcgaccccg ccaacgtgtc ttggcccacg cactcatgtc atgttggtgt 540
tgggaggcca ctttttaagt agcacaaggc acctagctcg cagcaaggtg tccgaaccaa 600
agaagcggct gcagtggtgc aaacggggcg gaaacggcgg gaaaaagcca cgggggcacg 660
aattgaggca cgccctcgaa tttgagacga gtcacggccc cattcgcccg cgcaatggct 720
cgccaacgcc cggtcttttg caccacatca ggttacccca agccaaacct ttgtgttaaa 780
aagcttaaca tattataccg aacgtaggtt tgggcgggct tgctccgtct gtccaaggca 840
acatttatat aagggtctgc atcgccggct caattgaatc ttttttcttc ttctcttctc 900
tatattcatt cttgaattaa acacacatca acaatggcca tcaaagtcgg tattaacgga 960
ttcggacgaa tcggacgaat tgtgagtacc atagaaggtg atggaaacat gacccaacag 1020
aaacagatga caagtgtcgt cgacccacca gagcccaatt gagctcatac taacagtcga 1080
caacctgtcg aaccaattga tgactccccg acaatgtact aacacaggtc 1130
＜210＞ 12
＜211＞402bp
＜212＞ DNA
< 213 > is artificially synthesized
＜400＞ 1
atgccgagtt cgaaatttcc caagtacacg tgggaagaaa ttcggaaaca caacaaagac 60
acagattgct gggtggtgct gtacgatcgt gttttggacg ttacaaagtt tttaaacgag 120
catcctggtg gacttgatcc aataaatgat cttggtggct acgacgtcac caattcgttt 180
gagactatcg gacactcctc agccgcgctg gcccgctcaa aagaattcat tgtgggtgac 240
ttggacaagg actcaatccc accacaagtt gttcggaagg aggtgaagaa taaagttcca 300
ctgacacagt accaggcagg tggagaaatg atttcactac aatacatact gggaggtgtc 360
attgcgcttt tgcttcttct ttactacctg atggcggctt aa 402
＜210＞ 13
＜211＞133
＜212＞ PRT
< 213 > is artificially synthesized
＜400＞ 1
MPSSKFPKYT WEEIRKHNKD TDCWVVLYDR VLDVTKFLNE HPGGLDPIND LGGYDVTNSF 60
ETIGHSSAAL ARSKEFIVGD LDKDSIPPQV VRKEVKNKVP LTQYQAGGEM ISLQYILGGV 120
IALLLLLYYL MAA 133

Claims (11)

1. An engineered yarrowia lipolytica strain that produces glycyrrhetinic acid, comprising: the yarrowia lipolytica engineering bacterium genome integrates bAS, CYP88D6, CYP725A4 and CPR gene, and has the capability of synthesizing glycyrrhetinic acid from beta-balsamic alcohol, 11-beta-balsamic alcohol and 30-hydroxyl-11-balsamic alcohol by using glucose as a substrate.
2. The engineered yarrowia lipolytica strain of claim 1 for production of glycyrrhetinic acid, wherein: the lanosterol synthase (ERG7) site is knocked out from the genome of the yarrowia lipolytica engineering strain, and squalene oxidase (ERG1) and squalene synthase (ERG9) are integrated and expressed at the site.
3. The engineered yarrowia lipolytica strain of claim 1 or 2 that produces glycyrrhetinic acid, wherein: the genome of the yarrowia lipolytica engineering strain overexpresses truncated hydroxymethylglutarate reductase (trHMGR) and hydroxymethylglutarate synthetase (HMGS); wherein the truncated range of the truncated hydroxymethylglutarate reductase (trHMGR) is the first 300-500 amino acid sequences from the N-terminal of the protein, more preferably the truncated range is the first 450-500 amino acid sequences from the N-terminal of the protein, and the most preferred truncated sequence is the first 500 amino acid sequences from the N-terminal of the protein.
4. The engineered yarrowia lipolytica strain of claim 1 for production of glycyrrhetinic acid, wherein: the genome of the yarrowia lipolytica engineering strain is integrated with cytochrome b 5.
5. The engineered yarrowia lipolytica strain of claim 4, wherein: the cytochrome b5 gene sequence is shown in SEQ ID NO.9 and is derived from trypanosoma griseus.
6. The method of constructing engineered yarrowia lipolytica strain of claim 1, wherein: the method comprises the following steps: constructing and obtaining glycyrrhetinic acid biosynthesis expression module plasmid: beta-amyrin synthase bAS expression module plasmid, cytochrome P450 oxidase 88D6CYP88D6 expression module plasmid, 11/30-oxidation-beta-amyrin synthase CYP725A4 expression module plasmid and cytochrome P450 reductase CPR expression module plasmid, integrating the glycyrrhetinic acid biosynthesis module on yarrowia lipolytica tool plasmid, linearizing the plasmid integrated with the glycyrrhetinic acid biosynthesis module, and introducing the linearized plasmid into yarrowia lipolytica to obtain yarrowia lipolytica engineering bacteria integrated with the glycyrrhetinic acid biosynthesis module on the genome.
7. The construction method according to claim 1, characterized in that: for purposes of conjugation to engineering, the lanosterol synthase (ERG7) site of the yarrowia lipolytica genome is recombinantly knocked out, at which site squalene oxidase (ERG1) and squalene synthase (ERG9) are expressed integratedly, to direct metabolic flow to 2, 3-oxidosqualene;
and/or recombinant engineering of the yarrowia lipolytica genome as follows: enhancing the flux of the MVA metabolic pathway by overexpressing a truncated hydroxymethylglutarate reductase (trHMGR) and a hydroxymethylglutarate synthetase (HMGS); wherein the truncated range of the truncated hydroxymethylglutarate reductase (trHMGR) is the first 300-500 amino acid sequences from the N-terminal of the protein, more preferably the truncated range is the first 450-500 amino acid sequences from the N-terminal of the protein, and the most preferred truncated sequence is the first 500 amino acid sequences from the N-terminal of the protein;
and/or incorporating cytochrome b5 on the yarrowia lipolytica strain.
8. The construction method according to claim 1, characterized in that: the yarrowia lipolytica tool plasmid is a single-copy integrated plasmid or a multi-copy integrated plasmid, and the single-copy integrated plasmid is a pINA1269 plasmid; the multicopy integration plasmid is pINA 1292.
9. Use of the yarrowia lipolytica engineered strain of any one of claims 1-5 for the production of glycyrrhetinic acid for the synthesis of glycyrrhetinic acid using glucose as substrate.
10. Use according to claim 9, characterized in that: the application method comprises the following steps:
culturing yarrowia lipolytica engineering strain for producing glycyrrhetinic acid to obtain seed solution;
inoculating the seed solution into a fermentation medium containing glucose and essential metal elements and nutrient substances for growth of yarrowia lipolytica, and performing fed-batch fermentation, wherein the pH control range in the fermentation process is 5.6-6.4; fed-batch glucose was controlled at a concentration of 20-40 g/L.
11. Use according to claim 10, characterized in that: the fermentation temperature is 28-32 ℃; the fermentation time is preferably 120h to 150 h.
CN202111107802.9A 2021-09-22 2021-09-22 Yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as substrate, construction and application thereof Active CN113930348B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111107802.9A CN113930348B (en) 2021-09-22 2021-09-22 Yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as substrate, construction and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111107802.9A CN113930348B (en) 2021-09-22 2021-09-22 Yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as substrate, construction and application thereof

Publications (2)

Publication Number Publication Date
CN113930348A true CN113930348A (en) 2022-01-14
CN113930348B CN113930348B (en) 2024-07-12

Family

ID=79276301

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111107802.9A Active CN113930348B (en) 2021-09-22 2021-09-22 Yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as substrate, construction and application thereof

Country Status (1)

Country Link
CN (1) CN113930348B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114774503A (en) * 2022-06-20 2022-07-22 中国中医科学院中药研究所 Squalene epoxidase and coding gene and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106566815A (en) * 2016-11-04 2017-04-19 北京理工大学 Saccharomyces cerevisiae engineered strain used for producing glycyrrhetinic acid and precursor thereof and construction method of saccharomyces cerevisiae engineered strain
CN106987533A (en) * 2017-03-23 2017-07-28 石河子大学 A kind of construction method for the saccharomyces cerevisiae engineered yeast that can synthesize enoxolone
WO2018120983A1 (en) * 2016-12-28 2018-07-05 中国中医科学院中药研究所 Glycyrrhetinic acid-producing recombinant saccharomyces cerevisiae, construction method for same, and uses thereof
CN110628805A (en) * 2019-09-19 2019-12-31 天津大学 Recombinant bacterium for finely regulating expression of saccharomyces cerevisiae ERG7 and construction method
US20210071150A1 (en) * 2018-04-09 2021-03-11 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Method for increasing the yield of oxidosqualene, triterpenes and/or triterpenoids and host cell therefore

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106566815A (en) * 2016-11-04 2017-04-19 北京理工大学 Saccharomyces cerevisiae engineered strain used for producing glycyrrhetinic acid and precursor thereof and construction method of saccharomyces cerevisiae engineered strain
WO2018120983A1 (en) * 2016-12-28 2018-07-05 中国中医科学院中药研究所 Glycyrrhetinic acid-producing recombinant saccharomyces cerevisiae, construction method for same, and uses thereof
CN106987533A (en) * 2017-03-23 2017-07-28 石河子大学 A kind of construction method for the saccharomyces cerevisiae engineered yeast that can synthesize enoxolone
US20210071150A1 (en) * 2018-04-09 2021-03-11 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Method for increasing the yield of oxidosqualene, triterpenes and/or triterpenoids and host cell therefore
CN110628805A (en) * 2019-09-19 2019-12-31 天津大学 Recombinant bacterium for finely regulating expression of saccharomyces cerevisiae ERG7 and construction method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
沈湛云;刘春生;黄建梅;林宏英;苏爽;: "甘草β-香树酯醇合成酶的多态性对其催化效率的影响研究", 中国中药杂志, no. 22 *
赵鹤云;黄瑛;杨江科;徐莉;闫云君;: "解脂耶氏酵母表达系统研究进展", 生物加工过程, no. 03 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114774503A (en) * 2022-06-20 2022-07-22 中国中医科学院中药研究所 Squalene epoxidase and coding gene and application thereof

Also Published As

Publication number Publication date
CN113930348B (en) 2024-07-12

Similar Documents

Publication Publication Date Title
CN109402158B (en) Recombinant expression plasmid vector for producing fucosyllactose, metabolic engineering bacteria and production method
CN111575220B (en) Recombinant escherichia coli for synthesizing 2&#39; -fucosyllactose, and construction method and application thereof
CN111778167B (en) Saccharomyces cerevisiae engineering bacterium for high yield of betulinic acid and construction method and application thereof
CN110117601B (en) Grifola frondosa glucan synthase, encoding gene and application thereof
CN112501095B (en) Construction method and application of recombinant escherichia coli for synthesizing 3-fucose
CN112280698B (en) Saccharomyces cerevisiae engineering bacteria for high-yield yacholanol type sesquiterpene and construction method and application thereof
US20210371843A1 (en) Genetically Engineered Bacteria, Its Construction Method And Its Application In Producing Nad+ Method
CN112175848B (en) Yeast strain for producing patchouli alcohol and construction method and application thereof
CN111471602B (en) Construction method and application of mucor circinelloides engineering strain for efficiently synthesizing gamma-linolenic acid by using cellulose
CN112195110A (en) Recombinant aspergillus oryzae strain and kojic acid fermentation method and application thereof
CN114262702A (en) Application of ergothioneine synthesis gene in reconstruction of ergothioneine metabolic pathway in corynebacterium glutamicum and method thereof
CN113930348B (en) Yarrowia lipolytica engineering strain for biosynthesis of glycyrrhetinic acid by taking glucose as substrate, construction and application thereof
CN116064345A (en) Non-antibiotic genetic engineering bacteria for efficiently producing fucosyllactose and application thereof
CN113308442B (en) Recombinant saccharomyces cerevisiae strain and construction method thereof
WO2024140379A1 (en) Enzyme, strain for producing salidroside, and production method
CN113174399A (en) Recombinant saccharomyces cerevisiae strain and fermentation method thereof
CN114525215B (en) Recombinant strain for producing terpenoid, construction method thereof, method for producing terpenoid through fermentation and application of recombinant strain
CN114107158B (en) Recombinant corynebacterium glutamicum for high-yield and high-purity isomaltulose and application thereof
CN114736918A (en) Recombinant escherichia coli for producing salidroside through integrated expression and application thereof
CN114410492A (en) Engineering bacterium for biosynthesis of cucurbitadienol by taking glucose as substrate, construction and application thereof
CN113832090A (en) Recombinant bacillus subtilis natto for high yield of vitamin K2, preparation method and application
CN114250155A (en) Trichoderma reesei engineering bacterium capable of highly producing cellulase under condition of taking glucose as carbon source and construction method and application thereof
LU102870B1 (en) Recombinant corynebacterium strain for modifying 5&#39;-end sequence of 4-hydroxy-tetrahydrodipicolinate synthase (hts) gene and use thereof
CN111718948B (en) Gene and application thereof in production of mannich
CN118109383B (en) Recombinant bacterium for producing ectoin and construction method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Zhao Yunxian

Inventor after: Yang Zhibin

Inventor after: Cui Jinwang

Inventor after: Hu Jianglin

Inventor after: Show all music

Inventor before: Zhao Yunxian

Inventor before: Li Di

Inventor before: Yang Zhibin

Inventor before: Cui Jinwang

Inventor before: Tian Haobo

Inventor before: Hu Jianglin

Inventor before: Show all music

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant